These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1972130)

  • 21. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
    Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
    Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
    Mahendra P; Johnson D; Hood IM; Scott MA; Barker P; Bass G; Jestice HK; Bloxham DM; Boraks P; Wimperis JZ; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Jun; 17(6):973-8. PubMed ID: 8807102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
    Anselmo AP; Cavalieri E; Meloni G; Alimena G; Cantonetti M; Maurizi Enrici R; Tosti ME; Falchetto Osti M; Gianfelici V; Mandelli F
    Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantity and origin of transplanted autologous blood cells are independent factors associated with speed of postransplant hematological reconstitution.
    Rogulj D; Batinić D; Nemet D; Petrovecki M
    Croat Med J; 1999 Sep; 40(3):404-8. PubMed ID: 10411969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience.
    López R; Martino R; Sureda A; Nomdedéu J; Briones J; Martin-Henao G; García J; Brunet S; Sierra J
    Haematologica; 1999 Apr; 84(4):350-5. PubMed ID: 10190950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.
    Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F
    Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation.
    de la Rubia J; Saavedra S; Sanz GF; Martín G; Moscardó F; Martínez J; Jarque I; Jiménez C; Sanz MA
    Bone Marrow Transplant; 2001 Jan; 27(1):21-5. PubMed ID: 11244434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of moderate-grade and high-grade malignant lymphoma with autologous hematopoietic stem cell transplantation].
    Wang AL; He ZD; Luo Y; Xiao LX; Liu XY; Zhu YH
    Ai Zheng; 2003 Dec; 22(12):1317-20. PubMed ID: 14693059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.